Michael H. Weisman, MD

Chair, Division of Rheumatology
Director, Division of Rheumatology

Michael H. Weisman, MD, is the Chair and Director of the Division of Rheumatology at Cedars-Sinai Medical Center.

Dr. Weisman's academic and research interests involve the genetic risk, epidemiology, treatment and outcome of rheumatic diseases, including clinical trials, outcomes research and health services research and genetic susceptibility/severity studies of patients with chronic rheumatic disease. He currently is an investigator for National Institutes of Health-sponsored studies in systemic lupus erythematosus, osteoarthritis, ankylosing spondylitis and rheumatoid arthritis.

Board certified in internal medicine and rheumatology, Dr. Weisman has participated on agencies, review panels and advisory boards for numerous healthcare organizations, including the FDA Arthritis Advisory Committee, Veterans Administration Cooperative Studies Program, National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS), National Heart, Lung, and Blood Institute (NHLBI), Medical Board of California, Arthritis Foundation, American College of Rheumatology, Institute of Medicine (National Academy of Sciences) and National Board of Medical Examiners.

Dr. Weisman has published more than 200 peer-reviewed papers and four books, and he recently co-edited the newest edition of Rheumatology, a major international textbook in the field of rheumatic diseases. In addition, he serves as a reviewer and editor for many journals in the field of rheumatology, including the New England Journal of Medicine, Arthritis and Rheumatism, Journal of Rheumatology, Musculoskeletal Medicine, Annals of Rheumatic Diseases and Osteoarthritis and Cartilage.

Born in Los Angeles at Cedars of Lebanon Hospital (which would later become Cedars-Sinai Medical Center), Dr. Weisman attended medical school at the University of Chicago and completed his internship, residency and fellowship in rheumatology at University of California, San Diego School of Medicine.